ALK F1174C

CI-VAR-00001068Explore in graph →NP_004295.2:p.Phe1174CysNM_004304.4:c.3521T>GClinVar 375887 CIViC 1492 rs1057519697

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ALK F1174C	Crizotinib	Predictive	D	Supports Resistance	—	submitted	EID4430 In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK F1174C co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC) PMID 24675041 · Friboulet et al., 2014 · Open in CIViC	civic
Malignant Neoplasm2
EML4::ALK Fusion AND ALK F1174C	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	3	submitted	EID11079 From a mutation assay that generated crizotinib resistant mutations in EML4::ALK, the five most resistant mutations found were introduced into Ba/F3 cells and tested with the ALK inhibitor TAE684. EML… (full text at CIViC)

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375887	Likely pathogenic	criteria provided, single submitter	1	ALK-related disorder; Neuroblastoma	germline/somatic	2	May 11, 2023	clinvar